Startups
Back to overview
Immunara is developing a novel immune-priming technology based on single domain antibodies to direct patients’ own immune systems against cancer.
Immunara is developing a novel precision immunotherapy designed to prime the immune system against cancer. By utilising single domain antibodies (SdAb), our approach selectively delivers immune-priming components to antigen-presenting cells (APCs), the ‘teacher cells‘ of the immune system. Our SdAbs guide antigens and immunomodulators directly to APCs, unlocking stronger, highly specific immune responses against cancer. Our technology also has the potential to direct tailored immune responses against autoimmune and inflammatory diseases.
BioBusiness Masterclass
Year of participation
2026